Medicamen Organics Limited promoter group members, including Bal Kishan Gupta, Ashutosh Gupta, and Ishaan Gupta, confirmed that no encumbrance was created or invoked on the equity shares held by them or any Persons Acting in Concert (PACs) during the financial year ended March 31, 2026. The disclosures, filed under Regulation 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, cover shareholdings amounting to INR 6,56,85,600, INR 59,14,000, and INR 70,500 respectively.

The declarations were addressed to the Manager-Listing at the National Stock Exchange of India Limited and the Audit Committee of Medicamen Organics . Bal Kishan Gupta, aged 73 years, and Ashutosh Gupta, aged 45 years, provided the confirmations in their capacity as promoters of the company. Ishaan Gupta, aged 19 years and son of Shri Ashutosh Gupta, submitted the declaration as a member of the promoter group.

The filings ensure compliance with the Takeover Regulations, which mandate disclosures regarding any charges or pledges on promoter shareholdings. The confirmations stated that no such encumbrance, whether direct or indirect, was established or triggered during the specified period.

The documents, dated April 07, 2026, were signed by the promoters and submitted for the records of the stock exchange and the company's audit committee.

Medicamen Organics Limited reported a consolidated net loss of ₹401.94 lakh for the financial year ended March 31, 2026, a significant reversal from the net profit of ₹404.71 lakh recorded in the previous year. Total revenue for the period fell to ₹2270.91 lakh from ₹3828.27 lakh in FY25, driven by a decrease in revenue from operations. The company's board approved the audited standalone and consolidated financial results for the half-year and financial year ended March 31, 2026, during a meeting held on May 29, 2026.

The statutory auditors, M/s N C Raj & Associates, issued an audit report with an unmodified opinion on the financial results. However, the auditors included an emphasis of matter paragraph noting that the company did not make provisions for legal cases filed by creditors Prakash Parcel Services Limited and Multani Pharmaceuticals Limited, as the matters are pending in court. Additionally, no provision was made for demands raised by tax authorities, including Income Tax and GST, which are currently under appeal.

Financial Performance

The standalone financial results for FY26 reflected a net loss of ₹304.54 lakh, compared to a net profit of ₹327.08 lakh in the previous year. Revenue from operations dropped to ₹2164.80 lakh from ₹3708.77 lakh in FY25. Total expenses for the year increased to ₹2602.48 lakh from ₹3279.58 lakh in the prior year, primarily due to higher costs of materials consumed and employee benefits expenses.

Consolidated Results

Asset Quality and Provisions

The auditor's report highlighted that the company wrote off an amount of ₹33.09 lakh representing an outstanding GST refund balance deemed no longer recoverable. In the consolidated results, the subsidiary Grande Etoile Pharmaceuticals Limited wrote off a receivable of ₹110 lakh from Medi Hub Organic Limited, Nepal, due to the project's non-implementation and the customer's inability to pay. The management assessed that the recoverable amount of assets remains higher than their carrying value, and thus no impairment was recorded.

Fund Utilization

The company reported a deviation in the utilization of proceeds from its Initial Public Offering (IPO). Shareholders approved a variation in the objects of the issue via a special resolution on February 26, 2026. Unutilized IPO proceeds amounting to ₹162.44 lakh, originally allocated for product registration in international markets, were reallocated to meet working capital requirements. For the preferential issue of share warrants, the company confirmed that funds were utilized in accordance with the disclosed objects, with no deviation reported.